+41(0)916011700 [email protected] www.dipharma.ch

MIGLUSTAT DIPHARMA IS NOW AVAILABLE IN SWITZERLAND Chiasso, Switzerland, February 16th 2021 – – Swiss-based Dipharma S.A. (“Dipharma”) today announced that its proprietary product Miglustat Dipharma 100 mg capsules is now available in Switzerland.

Miglustat Dipharma, a generic equivalent to Actelion’s (Johnson & Johnson) Zavesca®, is indicated for the oral treatment of adult patients with mild to moderate type 1 Gaucher Disease for whom enzyme replacement therapy is unsuitable, as well as for the treatment of progressive neurological manifestations in adult and pediatric patients with Niemann-Pick type C Disease.

Miglustat Dipharma is distributed in Switzerland by EffRx Pharmaceuticals SA, a company specialized in the commercialization of orphan drugs.

The agreement with EffRx Pharmaceuticals marks another milestone in Dipharma’s mission to offer improved solutions to patients suffering from inborn errors of metabolism, as well as providing physicians and payers with high quality therapeutic alternatives which can generate important cost savings for healthcare systems.

Miglustat Dipharma 100 mg capsules is currently also available in the main EU countries through a network of selected commercial partners.

About Dipharma Dipharma S.A. is a Swiss specialty pharmaceutical company, developing high quality, improved, medicines for rare diseases. Dipharma S.A. is part of a third-generation group of family-owned companies that have grown to a global presence. With a portfolio of generic orphan products for the treatment of Phenylketonuria, Gaucher Disease, Hereditary Tyrosinemia Type 1, Urea Cycle Disorders and others, Dipharma S.A. provides improved solutions for patients affected by inborn metabolic diseases at an affordable cost and with a global reach. For more information, please visit www.dipharma.ch

About EffRx Pharmaceuticals EffRx Pharmaceuticals is a commercial-stage pharmaceutical company focused on the late stage development and commercialization of prescription medications for niche and orphan indications. The business model is centered around providing superior clinical and commercial value propositions for physicians, payers and patients.

EffRx pro-actively seeks in-licensing opportunities for Europe in niche therapeutic areas, with a primary interest for rare diseases, where EffRx has received an orphan drug designation (ODD) from the FDA for a pipeline asset. For more information, please visit www.effrx.com EffRx’s go-to-market competence is proven by the development, launch and successful expansion of Binosto® in a highly competitive European market. Our lead commercialized product, Binosto® for the treatment of osteoporosis, is marketed in the US as well as selected European and Asian countries.

Zavesca® is a registered trademark of Actelion (Johnson & Johnson). In the European Union Zavesca® was first approved in November 2002 for the treatment of type 1 Gaucher Disease and in January 2009 it obtained authorization for the treatment of Niemann-Pick disease type C.

DISCLAIMER This press release may contain certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, including scientific, business, economic and financial factors, which could cause actual results to differ materially from those anticipated in the forward-looking statements. The company assumes no responsibility to update forward-looking statements or adapt them to future events or developments. Dipharma S.A. operates respectfully of any third-party IP rights and/or regulatory exclusivities that may exists in each specific country. This press release may contain information on pharmaceuticals that are not currently approved or available in your country or region.